Abstract
Sezolamide, a potent topical carbonic anhydrase inhibitor previously known as MK-417, was studied to determine its ocular hypotensive activity in patients with elevated intraocular pressure while on continuing therapy with topical timolol. This was a three-centre, double-masked, randomised, placebo-controlled, parallel study in 36 patients with bilateral primary open angle glaucoma or ocular hypertension on therapy receiving 0.5% timolol twice daily, with a morning intraocular pressure greater than or equal to 22 mmHg in both eyes 2–4 hours following an 8 a.m. dose of timolol. Sezolamide 1.8% or placebo twice daily was added to treatment with timolol on the evening of day 1 and continued for 2 weeks. Twelve-hour diurnal curves were performed before the study on day 1 (timolol alone) and on day 15. Intraocular pressure measurements were also taken on days 2 and 8 at 8 a.m. and 9 a.m. Patients who received timolol and sezolamide showed additional intraocular pressure reductions from day 1 (timolol alone) of 8.0 to 15.5%, which were significant at all times. At hours 1, 2, 4 and 8 the reductions in intraocular pressure observed in the group receiving sezolamide and timolol were significantly greater than those in the group receiving timolol and placebo.
Similar content being viewed by others
Article PDF
References
Bron AM, Lippa EA, Hofmann HM, Feicht B, Royer J, Brunner-Ferber F, et al.: MK-927: a topically effective carbonic anhydrase inhibitor in patients. Arch Ophthalmol 1989, 107: 1143–6.
Pfeiffer N, Hennekes R, Lippa EA, Grehn F, Garus H, Brunner-Ferber FL : Single-dose efficacy of a novel topical carbonic anhydrase inhibitor. Br J Ophthalmol 1990, 74: 405.
Higginbotham EJ, Kass MA, Lippa EA, Batenhorst RL, Panebianco DL, Wilensky JT : MK-927, a topical carbonic anhydrase inhibitor; dose response and duration of action. Arch Ophthalmol 1990, 108: 65.
Serle JB, Lustgarten JS, Lippa EA, Camras CB, Panebianco DL, Podos SM : MK-927, a topical carbonic anhydrase inhibitor: dose response and reproducibility. Arch Ophthalmol 1990, 108: 838.
Lippa EA, Aasved H, Airaksinen PJ, AIm A, Bertelsen T, Calissendorff B, et al.: Multiple-dose dose-response relationship for the topical carbonic anhydrase inhibitor MK-927. Arch Ophthalmol 1991, 109: 46.
Baldwin J, Ponticello G, Anderson P, Christy M, Murcko M, Randall W, et al.: Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J Med Chem 1989, 32: 2510.
Diestelhorst M, Béchetoille A, Lippa EA, Brunner-Ferber FL, Krieglstein GK : Zur Stereospezifität der Augendrucksenkung eines lokal applizierten Karboanhydrasehemmers. Fortschr Ophthalmol 1990, 87: 131.
Bron A, Lippa EA, Gunning F, Bénichou MD, Lesure P, Sirbat D, et al.: Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors MK-417 and MK-927. Arch Ophthalmol 1991, 109: 50.
Lippa EA, Sherwood M, Laibovitz RM, Miller E, McMahon C, Clineschmidt C, Caprioli J : MK-417 vs. timolol : comparative activity. Invest Ophthalmol Vis Sci 1990, 31 (suppl): 232.
Becker B : Decrease in intraocular pressure by a carbonic anhydrase inhibitor, Diamox. Am J Ophthamol 1954, 37: 13.
Katz IM, Hubbard WA, Getson AJ, Gould AL : Intraocular pressure decrease in normal volunteers following timolol ophthalmic solution. Invest Ophthalmol Vis Sci 1976, 15: 498.
Boger WP, III, Puliafito CA, Steinert RF, Langston DP : Long-term experience with timolol ophthalmic solution in patients with open angle glaucoma. Ophthalmology 1978, 85: 259.
Nielsen NV : Timolol. Hypotensive effect, used alone and in combination for treatment of increased intraocular pressure. Acta Ophthalmol 1978, 56: 504–9.
Bischoff P : Erfahrungen mit timolol in der glaukom therapie. Klin Monatsbl Augenheilkd 1978, 173: 202.
Leydhecker W, Krieglstein GK : The intraocular pressure responses of low-dose bupranolol (Ophtorenin) and methazolamide (Neptazane) in glaucomatous eyes. A controlled clinical study. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1979, 210: 135.
MacDonald MJ, Gore SM, Cullen PM, Phillips CI : Comparison of ocular hypotensive effects of acetazolamide and atenolol. Br J Ophthalmol 1977, 61: 345.
Smith JP, Weeks RH, Newland EF, Ward RL : Betaxolol and acetazolamide. Combined ocular hypotensive effect. Arch Ophthalmol 1984, 102: 1794.
Keates EU : Evaluation of timolol maleate combination therapy in chronic open-angle glaucoma. Am J Ophthalmol 1979, 88: 565.
Dailey RA, Brubaker RF, Bourne WM : The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol 1982, 93: 232.
Coakes RL, Brubaker RF : The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol 1978, 96: 2045.
Yablonski ME, Zimmerman TJ, Waltman SR, Becker B : A fluorophotometric study of the effect of topical timolol on aqueous humour dynamics. Exp Eye Res 1978, 27: 135.
Zimmerman TJ, Harbin R, Pett M, Kaufman HE : Timolol and facility of outflow. Invest Ophthalmol Vis Sci 1977, 16: 623.
Berson FG, Epstein DL : Separate and combined effect of timolol maleate and acetazolamide in open-angle glaucoma. Am J Ophthalmol 1981, 92: 788.
Kass MA, Korey M, Gordon M, Becker B : Timolol and acetazolamide. A study of concurrent administration. Arch Ophthalmol 1982, 100: 941.
Scharrer A, Ober M : Timolol and acetazolamide in the treatment of increased intraocular pressure (author's translation). Albrecht Von Graefes Arch Klin Exp Ophthalmol 1979, 212: 129.
Hoskins HD, Kass MA, editors. Adrenergic antagonists. In: Becker-Shaffers's diagnosis and therapy of the glaucomas, 6th ed. St. Louis, Mosby, 1989, p. 454.
Maren TH : The rates of movement of NA+, Cl−, and HCO−3 from plasma to posterior chamber: effect of acetazolamide and relation to the treatment of glaucoma. Invest Ophthalmol 1976, 15: 356.
Maren TH : Carbonic anhydrase: general perspectives and advances in glaucoma research. Drug Dev Res 1987, 10: 255.
Calissendorff B, Maren N, Wettrell K, Ostberg A : Timolol versus pilocarpine separately or combined with acetazolamide effects on intraocular pressure. Acta Ophthalmol 1980, 58: 624.
Buclin T., Biollaz J, Lippa EA, Brunner-Ferber F, Van Melle G, Munafo A, et al.: Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during prolonged ocular administration to normal subjects. J Clin Pharmacol Ther In press.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gunning, F., Béchetoille, A., Lippa, E. et al. Sezolamide: Additivity to timolol twice daily. Eye 6, 525–529 (1992). https://doi.org/10.1038/eye.1992.111
Issue Date:
DOI: https://doi.org/10.1038/eye.1992.111
Keywords
This article is cited by
-
Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: A multiple-dose efficacy study
Graefe's Archive for Clinical and Experimental Ophthalmology (1993)